afimkibart vs duvakitug

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: TL1A · full Ulcerative Colitis pipeline

afimkibart

Developed by Roche and partners

Phase 3 in Ulcerative Colitismonoclonal antibody
Partial signal

NCT04090411 · Phase 2 · completed

This was a randomized, double-blind, placebo-controlled Phase 2 study (N=246) in moderate-to-severe ulcerative colitis, with Week 14 clinical remission on the Mayo score as the primary endpoint. Although remission rates were numerically higher in all afimkibart dose groups (25.5%, 23.3%, 23.9%) than placebo (11.6%), the differences were not statistically significant (one-sided p-values 0.055–0.082; 90% confidence intervals crossed zero), so the primary efficacy comparison was not met. The well-controlled design is real evidence, but because the primary endpoint was missed, the trial does not rise to strong evidence of benefit.

Next expected readout: January 2027 · NCT06589986 (registry estimate)

Reported efficacy

Induction Period: Percentage of Participants Who Achieved Clinical Remission at Week 14; Induction Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (From initiation of study treatment to either first dose in the chronic period or end of safety follow-up, whichever occurs first. (Approximately 16 weeks plus 12-week safety follow-up, if applicable.)); Induction Period: Number of Participants With Serious Adverse Events (SAEs) (From initiation of study treatment to either first dose in the chronic period or end of safety follow-up, whichever occurs first. (Approximately 16 weeks plus 12-week safety follow-up, if applicable.)); Induction Period: Number of Participants With AEs or SAEs Leading to Discontinuation (From initiation of study treatment to either first dose in the chronic period or end of safety follow-up, whichever occurs first. (Approximately 16 weeks plus 12-week safety follow-up, if applicable.)); Chronic Period: Number of Participants With TEAEs (From first dose of study treatment in the chronic period to end of safety follow-up. (Approximately 40 weeks plus 12-week safety follow-up.)); Chronic Period: Number of Participants With SAEs (From first dose of study treatment in the chronic period to end of safety follow-up. (Approximately 40 weeks plus 12-week safety follow-up.)); Chronic Period: Number of Participants With AEs or SAEs Leading to Discontinuation (From first dose of study treatment in the chronic period to end of safety follow-up. (Approximately 40 weeks plus 12-week safety follow-up.)): Induction Period: Percentage of Participants Who Achieved Clinical Remission at Week 14 (At Week 14): Induction Period: Placebo 11.6% (95% CI 5.77-22.88) vs Induction Period: PF-06480605 50 mg 25.5% (95% CI 15.44-37.19) vs Induction Period: PF-06480605 150 mg 23.3% (95% CI 14.98-33.98) vs Induction Period: PF-06480605 450 mg 23.9% (95% CI 16.58-32.06); p=0.0545 (Induction Period: Placebo vs Induction Period: PF-06480605 50 mg), p=0.0823 (Induction Period: Placebo vs Induction Period: PF-06480605 150 mg), p=0.0642 (Induction Period: Placebo vs Induction Period: PF-06480605 450 mg) (missed)

Result source: NCT04090411

duvakitug

Developed by Teva Pharmaceutical Industries and partners

Phase 3 in Ulcerative Colitismonoclonal antibody (IgG1-λ2)
Partial signal

NCT05499130 · Phase 2b · completed

Randomized, double-blind, placebo-controlled dose-ranging basket study in UC and Crohn's disease. In UC the high dose separated from placebo on clinical remission (p=.003) and the low dose was borderline (p=.050); in Crohn's disease endoscopic response was 47.8% (high dose) and 26.1% (low dose) vs 13.0% placebo. The sponsor reports one-sided p-values at a 0.10 significance level, a lenient threshold, and each cohort was modest in size. A well-designed Phase 2b with a dose-dependent, partly borderline result is capped at moderate. Progressed to Phase 3.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: May 2028 · NCT07184996 (registry estimate)

Reported efficacy

Clinical remission (mMS) at week 14: UC cohort, clinical remission at week 14: 36% (450 mg) / 48% (900 mg) vs 20% placebo, placebo-adjusted 16% (p=.050) / 27% (p=.003). CD cohort, endoscopic response: 26.1% (low dose) / 47.8% (high dose) vs 13.0% placebo. P-values are one-sided at a 0.10 significance level. (met)

Result source: NCT05499130

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointafimkibartduvakitug
Clinical remission (induction)23.9% vs 11.6%+12.3 vs placebo450 mg · wk 14 · n 88NCT04090411
2 other results
  • 23.3% vs 11.6% 150 mg · wk 14 · n 60 · Phase 2 · primary NCT04090411
  • 25.5% vs 11.6% 50 mg · wk 14 · n 47 · Phase 2 · primary NCT04090411
47.8% vs 20.5%+27.3 vs placebo900 mg · wk 14 · n 46NCT05499130
3 other results
  • 36.2% vs 20.5% 450 mg · wk 14 · n 47 · Phase 2b · primary NCT05499130
  • 23.9% vs 9.1% 900 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
  • 29.8% vs 9.1% 450 mg · wk 14 · n 47 · Phase 2b · secondary NCT05499130
Clinical remission (maintenance)—Trial running · NCT06589986—Trial running · NCT07185009
Clinical response (induction)—Trial running · NCT0658998669.6% vs 52.3%+17.3 vs placebo900 mg · wk 14 · n 46NCT05499130
3 other results
  • 73.9% vs 50% 900 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
  • 80.9% vs 52.3% 450 mg · wk 14 · n 47 · Phase 2b · secondary NCT05499130
  • 83% vs 50% 450 mg · wk 14 · n 47 · Phase 2b · secondary NCT05499130
Endoscopic improvement (induction)40.9% vs 18.6%+22.3 vs placebo450 mg · n 88NCT04090411
8 other results
  • 36% vs 18.6% 450 mg (Induction) to 50 mg (Chronic) · n 25 · Phase 2 · secondary NCT04090411
  • 37.5% vs 18.6% 450 mg (Induction) to 150 mg (Chronic) · n 24 · Phase 2 · secondary NCT04090411
  • 50% vs 18.6% 450 mg (Induction) to 450 mg (Chronic) · n 28 · Phase 2 · secondary NCT04090411
  • 38.3% vs 18.6% 150 mg · n 60 · Phase 2 · secondary NCT04090411
  • 37% vs 18.6% 150 mg (Induction) to 50 mg (Chronic) · n 27 · Phase 2 · secondary NCT04090411
  • 39.3% vs 18.6% 150 mg (Induction) to 150 mg (Chronic) · n 28 · Phase 2 · secondary NCT04090411
  • 40.4% vs 18.6% 50 mg · n 47 · Phase 2 · secondary NCT04090411
  • 38.1% vs 18.6% 50 mg (Induction) to 50 mg (Chronic) · n 42 · Phase 2 · secondary NCT04090411
—Trial running · NCT07185009
Corticosteroid-free remission (maintenance)—Trial running · NCT06589986—Trial running · NCT07185009

Clinical remission (induction)

afimkibart
23.9% vs 11.6%+12.3 vs placebo450 mg · wk 14 · n 88NCT04090411
2 other results
  • 23.3% vs 11.6% 150 mg · wk 14 · n 60 · Phase 2 · primary NCT04090411
  • 25.5% vs 11.6% 50 mg · wk 14 · n 47 · Phase 2 · primary NCT04090411
duvakitug
47.8% vs 20.5%+27.3 vs placebo900 mg · wk 14 · n 46NCT05499130
3 other results
  • 36.2% vs 20.5% 450 mg · wk 14 · n 47 · Phase 2b · primary NCT05499130
  • 23.9% vs 9.1% 900 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
  • 29.8% vs 9.1% 450 mg · wk 14 · n 47 · Phase 2b · secondary NCT05499130

Clinical remission (maintenance)

afimkibart
—Trial running · NCT06589986
duvakitug
—Trial running · NCT07185009

Clinical response (induction)

afimkibart
—Trial running · NCT06589986
duvakitug
69.6% vs 52.3%+17.3 vs placebo900 mg · wk 14 · n 46NCT05499130
3 other results
  • 73.9% vs 50% 900 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
  • 80.9% vs 52.3% 450 mg · wk 14 · n 47 · Phase 2b · secondary NCT05499130
  • 83% vs 50% 450 mg · wk 14 · n 47 · Phase 2b · secondary NCT05499130

Endoscopic improvement (induction)

afimkibart
40.9% vs 18.6%+22.3 vs placebo450 mg · n 88NCT04090411
8 other results
  • 36% vs 18.6% 450 mg (Induction) to 50 mg (Chronic) · n 25 · Phase 2 · secondary NCT04090411
  • 37.5% vs 18.6% 450 mg (Induction) to 150 mg (Chronic) · n 24 · Phase 2 · secondary NCT04090411
  • 50% vs 18.6% 450 mg (Induction) to 450 mg (Chronic) · n 28 · Phase 2 · secondary NCT04090411
  • 38.3% vs 18.6% 150 mg · n 60 · Phase 2 · secondary NCT04090411
  • 37% vs 18.6% 150 mg (Induction) to 50 mg (Chronic) · n 27 · Phase 2 · secondary NCT04090411
  • 39.3% vs 18.6% 150 mg (Induction) to 150 mg (Chronic) · n 28 · Phase 2 · secondary NCT04090411
  • 40.4% vs 18.6% 50 mg · n 47 · Phase 2 · secondary NCT04090411
  • 38.1% vs 18.6% 50 mg (Induction) to 50 mg (Chronic) · n 42 · Phase 2 · secondary NCT04090411
duvakitug
—Trial running · NCT07185009

Corticosteroid-free remission (maintenance)

afimkibart
—Trial running · NCT06589986
duvakitug
—Trial running · NCT07185009
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. afimkibart: 5 of 5 rows · duvakitug: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricafimkibartduvakitug
Endoscopic Remission
responder rate · % of participants
Induction
10.2% (n=88) vs 7% (n=43) placebo450 mga,b,c,d,e
NCT04090411 · Phase 2
show 8 more doses
8.3% (n=24) vs 7% (n=43) placebo450 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
21.4% (n=28) vs 7% (n=43) placebo450 mg (Induction) to 450 mg (Chronic)
NCT04090411 · Phase 2
16% (n=25) vs 7% (n=43) placebo450 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
10% (n=60) vs 7% (n=43) placebo150 mg
NCT04090411 · Phase 2
7.1% (n=28) vs 7% (n=43) placebo150 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
7.4% (n=27) vs 7% (n=43) placebo150 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
19.1% (n=47) vs 7% (n=43) placebo50 mg
NCT04090411 · Phase 2
11.9% (n=42) vs 7% (n=43) placebo50 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
17.4% (n=46) vs 6.8% (n=44) placebo @ 14wk*900 mga,b,c,d,e
NCT05499130 · Phase 2b · monotherapy · converted to % from 8 Participants as posted
show 1 more dose
17% (n=47) vs 6.8% (n=44) placebo @ 14wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 8 Participants as posted
Dropout rate
8.7%450 mgf
NCT04090411 · Phase 2
show 9 more results
—450 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
—450 mg (Induction) to 450 mg (Chronic)
NCT04090411 · Phase 2
—450 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
6.5%150 mg
NCT04090411 · Phase 2
—150 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
—150 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
2.1%50 mg
NCT04090411 · Phase 2
—50 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
2%500 mg IV
NCT02840721 · Phase 2 · registry result, not featured evidence
0%1800 mgf
NCT05499130 · Phase 2b · monotherapy
show 5 more results
0%1800 mg
NCT05499130 · Phase 2b · monotherapy
8.5%900 mg
NCT05499130 · Phase 2b · monotherapy
2.2%900 mg
NCT05499130 · Phase 2b · monotherapy
19.6%450 mg
NCT05499130 · Phase 2b · monotherapy
0%450 mg
NCT05499130 · Phase 2b · monotherapy
Discontinued due to AEs
1.1%450 mgf
NCT04090411 · Phase 2
show 9 more results
—450 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
—450 mg (Induction) to 450 mg (Chronic)
NCT04090411 · Phase 2
—450 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
1.6%150 mg
NCT04090411 · Phase 2
—150 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
—150 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
2.1%50 mg
NCT04090411 · Phase 2
—50 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
2%500 mg IV
NCT02840721 · Phase 2 · registry result, not featured evidence
0%1800 mgf
NCT05499130 · Phase 2b · monotherapy
show 5 more results
0%1800 mg
NCT05499130 · Phase 2b · monotherapy
2.1%900 mg
NCT05499130 · Phase 2b · monotherapy
2.2%900 mg
NCT05499130 · Phase 2b · monotherapy
8.7%450 mg
NCT05499130 · Phase 2b · monotherapy
0%450 mg
NCT05499130 · Phase 2b · monotherapy
Serious AEs
4.4%450 mgf
NCT04090411 · Phase 2
show 9 more results
3.8%450 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
13.8%450 mg (Induction) to 450 mg (Chronic)
NCT04090411 · Phase 2
7.7%450 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
1.6%150 mg
NCT04090411 · Phase 2
0%150 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
3.7%150 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
6.4%50 mg
NCT04090411 · Phase 2
10.9%50 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
6%500 mg IV
NCT02840721 · Phase 2 · registry result, not featured evidence
0%1800 mgf
NCT05499130 · Phase 2b · monotherapy
show 5 more results
0%1800 mg
NCT05499130 · Phase 2b · monotherapy
2.2%900 mg
NCT05499130 · Phase 2b · monotherapy
2.2%900 mg
NCT05499130 · Phase 2b · monotherapy
13%450 mg
NCT05499130 · Phase 2b · monotherapy
0%450 mg
NCT05499130 · Phase 2b · monotherapy
Most frequent reported AEs
450 mgf
headache 9.9% (placebo 2.2%)
fatigue 5.5% (placebo 0%)
pyrexia 5.5% (placebo 2.2%)
NCT04090411 · Phase 2
show 9 more results
450 mg (Induction) to 150 mg (Chronic)
anaemia 11.5% (placebo 8.9%)
colitis ulcerative 11.5% (placebo 0%)
sars-cov-2 test positive 11.5% (placebo 0%)
NCT04090411 · Phase 2
450 mg (Induction) to 450 mg (Chronic)
blood creatine phosphokinase increased 10.3% (placebo 4.4%)
anaemia 6.9% (placebo 8.9%)
covid-19 6.9% (placebo 0%)
NCT04090411 · Phase 2
450 mg (Induction) to 50 mg (Chronic)
colitis ulcerative 23.1% (placebo 0%)
sars-cov-2 test positive 15.4% (placebo 0%)
anaemia 11.5% (placebo 8.9%)
NCT04090411 · Phase 2
150 mg
anaemia 8.1% (placebo 8.9%)
injection site reaction 4.8% (placebo 2.2%)
headache 3.2% (placebo 2.2%)
NCT04090411 · Phase 2
150 mg (Induction) to 150 mg (Chronic)
nausea 10% (placebo 2.2%)
oropharyngeal pain 10% (placebo 2.2%)
sars-cov-2 test positive 10% (placebo 0%)
NCT04090411 · Phase 2
150 mg (Induction) to 50 mg (Chronic)
sars-cov-2 test positive 18.5% (placebo 0%)
colitis ulcerative 14.8% (placebo 0%)
injection site reaction 11.1% (placebo 2.2%)
NCT04090411 · Phase 2
50 mg
nausea 6.4% (placebo 2.2%)
urinary tract infection 6.4% (placebo 0%)
anaemia 4.3% (placebo 8.9%)
NCT04090411 · Phase 2
50 mg (Induction) to 50 mg (Chronic)
colitis ulcerative 17.4% (placebo 0%)
anaemia 8.7% (placebo 8.9%)
blood creatine phosphokinase increased 6.5% (placebo 4.4%)
NCT04090411 · Phase 2
500 mg IV
arthralgia 12%
colitis ulcerative 10%
abdominal pain 6%
NCT02840721 · Phase 2 · registry result, not featured evidence
1800 mgf
eczema 33.3% (placebo 0%)
influenza 33.3% (placebo 2.2%)
proteinuria 33.3% (placebo 0%)
NCT05499130 · Phase 2b · monotherapy
show 5 more results
1800 mg
abnormal uterine bleeding 14.3% (placebo 0%)
insomnia 14.3% (placebo 0%)
anaemia 0% (placebo 2.2%)
NCT05499130 · Phase 2b · monotherapy
900 mg
nasopharyngitis 6.5% (placebo 6.5%)
headache 2.2% (placebo 2.2%)
vomiting 2.2% (placebo 4.3%)
NCT05499130 · Phase 2b · monotherapy
900 mg
headache 4.3% (placebo 2.2%)
influenza 4.3% (placebo 2.2%)
anaemia 2.2% (placebo 2.2%)
NCT05499130 · Phase 2b · monotherapy
450 mg
headache 8.7% (placebo 2.2%)
anaemia 6.5% (placebo 2.2%)
nasopharyngitis 4.3% (placebo 6.5%)
NCT05499130 · Phase 2b · monotherapy
450 mg
nasopharyngitis 6.4% (placebo 6.5%)
upper respiratory tract infection 6.4% (placebo 4.3%)
vomiting 6.4% (placebo 4.3%)
NCT05499130 · Phase 2b · monotherapy

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 2b versus Phase 2.
  3. cPopulation context differs: registered conditions differ.
  4. dTreatment context has not been resolved for both arms.
  5. eThe assessment timepoint is not available for both results.
  6. fPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

afimkibart

Clinical Remission 23.9% (n=88) vs 11.6% (n=43) placebo @ 14wk450 mg
responder rate · % of participants
Induction
NCT04090411 · Phase 2
show 2 more results
23.3% (n=60) vs 11.6% (n=43) placebo @ 14wk150 mg
NCT04090411 · Phase 2
25.5% (n=47) vs 11.6% (n=43) placebo @ 14wk50 mg
NCT04090411 · Phase 2
Modified Remission 1 14.8% (n=88) vs 7% (n=43) placebo450 mg
responder rate · % of participants
Induction
NCT04090411 · Phase 2
show 8 more results
16% (n=25) vs 7% (n=43) placebo450 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
20.8% (n=24) vs 7% (n=43) placebo450 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
17.9% (n=28) vs 7% (n=43) placebo450 mg (Induction) to 450 mg (Chronic)
NCT04090411 · Phase 2
13.3% (n=60) vs 7% (n=43) placebo150 mg
NCT04090411 · Phase 2
22.2% (n=27) vs 7% (n=43) placebo150 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
23.1% (n=26) vs 7% (n=43) placebo150 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
14.9% (n=47) vs 7% (n=43) placebo50 mg
NCT04090411 · Phase 2
16.7% (n=42) vs 7% (n=43) placebo50 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
Modified Remission 2 31.8% (n=88) vs 11.6% (n=43) placebo450 mg
responder rate · % of participants
Induction
NCT04090411 · Phase 2
show 8 more results
28% (n=25) vs 11.6% (n=43) placebo450 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
33.3% (n=24) vs 11.6% (n=43) placebo450 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
35.7% (n=28) vs 11.6% (n=43) placebo450 mg (Induction) to 450 mg (Chronic)
NCT04090411 · Phase 2
35% (n=60) vs 11.6% (n=43) placebo150 mg
NCT04090411 · Phase 2
33.3% (n=27) vs 11.6% (n=43) placebo150 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
38.5% (n=26) vs 11.6% (n=43) placebo150 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
29.8% (n=47) vs 11.6% (n=43) placebo50 mg
NCT04090411 · Phase 2
31% (n=42) vs 11.6% (n=43) placebo50 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
Endoscopic Improvement 40.9% (n=88) vs 18.6% (n=43) placebo450 mg
responder rate · % of participants
Induction
NCT04090411 · Phase 2
show 8 more results
36% (n=25) vs 18.6% (n=43) placebo450 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
37.5% (n=24) vs 18.6% (n=43) placebo450 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
50% (n=28) vs 18.6% (n=43) placebo450 mg (Induction) to 450 mg (Chronic)
NCT04090411 · Phase 2
38.3% (n=60) vs 18.6% (n=43) placebo150 mg
NCT04090411 · Phase 2
37% (n=27) vs 18.6% (n=43) placebo150 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
39.3% (n=28) vs 18.6% (n=43) placebo150 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
40.4% (n=47) vs 18.6% (n=43) placebo50 mg
NCT04090411 · Phase 2
38.1% (n=42) vs 18.6% (n=43) placebo50 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
Endoscopic Remission 10.2% (n=88) vs 7% (n=43) placebo450 mg
responder rate · % of participants
Induction
NCT04090411 · Phase 2
show 8 more results
16% (n=25) vs 7% (n=43) placebo450 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
8.3% (n=24) vs 7% (n=43) placebo450 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
21.4% (n=28) vs 7% (n=43) placebo450 mg (Induction) to 450 mg (Chronic)
NCT04090411 · Phase 2
10% (n=60) vs 7% (n=43) placebo150 mg
NCT04090411 · Phase 2
7.4% (n=27) vs 7% (n=43) placebo150 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
7.1% (n=28) vs 7% (n=43) placebo150 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
19.1% (n=47) vs 7% (n=43) placebo50 mg
NCT04090411 · Phase 2
11.9% (n=42) vs 7% (n=43) placebo50 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
Clinical Remission 24% (n=25) @ 56wk450 mg (Induction) to 50 mg (Chronic)
responder rate · % of participants
No placebo or comparator arm
NCT04090411 · Phase 2
show 5 more results
25% (n=24) @ 56wk450 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
39.3% (n=28) @ 56wk450 mg (Induction) to 450 mg (Chronic)
NCT04090411 · Phase 2
29.6% (n=27) @ 56wk150 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
34.6% (n=26) @ 56wk150 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
31% (n=42) @ 56wk50 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
Sustained Clinical Remission 28.6% (n=7) @ 56wk450 mg (Induction) to 50 mg (Chronic)
responder rate · % of participants
No placebo or comparator arm
NCT04090411 · Phase 2
show 5 more results
50% (n=6) @ 56wk450 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
85.7% (n=7) @ 56wk450 mg (Induction) to 450 mg (Chronic)
NCT04090411 · Phase 2
50% (n=6) @ 56wk150 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
62.5% (n=8) @ 56wk150 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
50% (n=12) @ 56wk50 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
Sustained Modified Remission 1 25% (n=4) @ 56wk450 mg (Induction) to 50 mg (Chronic)
responder rate · % of participants
No placebo or comparator arm
NCT04090411 · Phase 2
show 5 more results
0% (n=3) @ 56wk450 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
80% (n=5) @ 56wk450 mg (Induction) to 450 mg (Chronic)
NCT04090411 · Phase 2
40% (n=5) @ 56wk150 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
66.7% (n=3) @ 56wk150 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
28.6% (n=7) @ 56wk50 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
Sustained Modified Remission 2 33.3% (n=9) @ 56wk450 mg (Induction) to 50 mg (Chronic)
responder rate · % of participants
No placebo or comparator arm
NCT04090411 · Phase 2
show 5 more results
60% (n=10) @ 56wk450 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
75% (n=8) @ 56wk450 mg (Induction) to 450 mg (Chronic)
NCT04090411 · Phase 2
70% (n=10) @ 56wk150 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
54.5% (n=11) @ 56wk150 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
42.9% (n=14) @ 56wk50 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
Sustained Endoscopic Improvement 46.2% (n=13) @ 56wk450 mg (Induction) to 50 mg (Chronic)
responder rate · % of participants
No placebo or comparator arm
NCT04090411 · Phase 2
show 5 more results
63.6% (n=11) @ 56wk450 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
80% (n=10) @ 56wk450 mg (Induction) to 450 mg (Chronic)
NCT04090411 · Phase 2
80% (n=10) @ 56wk150 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
61.5% (n=13) @ 56wk150 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
47.4% (n=19) @ 56wk50 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
Sustained Endoscopic Remission 66.7% (n=3) @ 56wk450 mg (Induction) to 50 mg (Chronic)
responder rate · % of participants
No placebo or comparator arm
NCT04090411 · Phase 2
show 5 more results
50% (n=2) @ 56wk450 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
66.7% (n=3) @ 56wk450 mg (Induction) to 450 mg (Chronic)
NCT04090411 · Phase 2
50% (n=2) @ 56wk150 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
25% (n=4) @ 56wk150 mg (Induction) to 150 mg (Chronic)
NCT04090411 · Phase 2
22.2% (n=9) @ 56wk50 mg (Induction) to 50 mg (Chronic)
NCT04090411 · Phase 2
Endoscopic Improvement 38.2% (n=45) @ 14wk500 mg IV
responder rate · % of participants
No placebo or comparator arm
NCT02840721 · Phase 2 · registry result, not featured evidence

+ 2 further endpoints in the CSV export.

duvakitug

Clinical Remission 47.8% (n=46) vs 20.5% (n=44) placebo @ 14wk900 mg
responder rate · % of participants
NCT05499130 · Phase 2b · monotherapy · converted to % from 22 Participants as posted
show 3 more results
23.9% (n=46) vs 9.1% (n=44) placebo @ 14wk*900 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 11 Participants as posted
36.2% (n=47) vs 20.5% (n=44) placebo @ 14wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 17 Participants as posted
29.8% (n=47) vs 9.1% (n=44) placebo @ 14wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 14 Participants as posted
Clinical Response 69.6% (n=46) vs 52.3% (n=44) placebo @ 14wk900 mg
responder rate · % of participants
NCT05499130 · Phase 2b · monotherapy · converted to % from 32 Participants as posted
show 3 more results
73.9% (n=46) vs 50% (n=44) placebo @ 14wk*900 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 34 Participants as posted
80.9% (n=47) vs 52.3% (n=44) placebo @ 14wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 38 Participants as posted
83% (n=47) vs 50% (n=44) placebo @ 14wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 39 Participants as posted
Endoscopic Improvement 50% (n=46) vs 22.7% (n=44) placebo @ 14wk900 mg
event count · % of participants
NCT05499130 · Phase 2b · monotherapy · converted to % from 23 Participants as posted
show 1 more result
44.7% (n=47) vs 22.7% (n=44) placebo @ 14wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 21 Participants as posted
Endoscopic Remission 17.4% (n=46) vs 6.8% (n=44) placebo @ 14wk900 mg
responder rate · % of participants
NCT05499130 · Phase 2b · monotherapy · converted to % from 8 Participants as posted
show 1 more result
17% (n=47) vs 6.8% (n=44) placebo @ 14wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 8 Participants as posted

Crohn's Disease

Shared mechanism: TL1A · full Crohn's Disease pipeline

afimkibart

Developed by Roche and partners

Phase 3 in Crohn's Diseasemonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT05910528 (registry estimate)

No aligned efficacy figure on record for this race.

duvakitug

Developed by Teva Pharmaceutical Industries and partners

Phase 3 in Crohn's Diseasemonoclonal antibody (IgG1-λ2)
Partial signal

NCT05499130 · Phase 2b · completed

Randomized, double-blind, placebo-controlled dose-ranging basket study in UC and Crohn's disease. In UC the high dose separated from placebo on clinical remission (p=.003) and the low dose was borderline (p=.050); in Crohn's disease endoscopic response was 47.8% (high dose) and 26.1% (low dose) vs 13.0% placebo. The sponsor reports one-sided p-values at a 0.10 significance level, a lenient threshold, and each cohort was modest in size. A well-designed Phase 2b with a dose-dependent, partly borderline result is capped at moderate. Progressed to Phase 3.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: August 2028 · NCT07923383 (registry estimate)

Reported efficacy

Clinical remission (mMS) at week 14: UC cohort, clinical remission at week 14: 36% (450 mg) / 48% (900 mg) vs 20% placebo, placebo-adjusted 16% (p=.050) / 27% (p=.003). CD cohort, endoscopic response: 26.1% (low dose) / 47.8% (high dose) vs 13.0% placebo. P-values are one-sided at a 0.10 significance level. (met)

Result source: NCT05499130

Results for Crohn's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointafimkibartduvakitug
Clinical remission (induction)—Trial running · NCT0681989154.3% vs 41.3%+13 vs placebo900 mg · wk 14 · n 46NCT05499130
3 other results
  • 37% vs 26.1% 900 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
  • 50% vs 41.3% 450 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
  • 37% vs 26.1% 450 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
Endoscopic response (induction)—Trial running · NCT0681989147.8% vs 13%+34.8 vs placebo900 mg · wk 14 · n 46NCT05499130
3 other results
  • 26.1% vs 13% 450 mg · wk 14 · n 46 · Phase 2b · primary NCT05499130
  • 39.1% vs 13% 900 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
  • 34.8% vs 13% 450 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
Clinical remission (maintenance)—Trial running · NCT06819891—Trial running · NCT07184944
Endoscopic response (maintenance)—Trial running · NCT06819891—Trial running · NCT07184944

Clinical remission (induction)

afimkibart
—Trial running · NCT06819891
duvakitug
54.3% vs 41.3%+13 vs placebo900 mg · wk 14 · n 46NCT05499130
3 other results
  • 37% vs 26.1% 900 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
  • 50% vs 41.3% 450 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
  • 37% vs 26.1% 450 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130

Endoscopic response (induction)

afimkibart
—Trial running · NCT06819891
duvakitug
47.8% vs 13%+34.8 vs placebo900 mg · wk 14 · n 46NCT05499130
3 other results
  • 26.1% vs 13% 450 mg · wk 14 · n 46 · Phase 2b · primary NCT05499130
  • 39.1% vs 13% 900 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130
  • 34.8% vs 13% 450 mg · wk 14 · n 46 · Phase 2b · secondary NCT05499130

Clinical remission (maintenance)

afimkibart
—Trial running · NCT06819891
duvakitug
—Trial running · NCT07184944

Endoscopic response (maintenance)

afimkibart
—Trial running · NCT06819891
duvakitug
—Trial running · NCT07184944
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

afimkibart: no structured comparison results are available for Crohn's Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. afimkibart: 0 of 4 rows · duvakitug: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricduvakitug
Dropout rate
0%1800 mga
NCT05499130 · Phase 2b · monotherapy
show 5 more results
0%1800 mg
NCT05499130 · Phase 2b · monotherapy
8.5%900 mg
NCT05499130 · Phase 2b · monotherapy
2.2%900 mg
NCT05499130 · Phase 2b · monotherapy
19.6%450 mg
NCT05499130 · Phase 2b · monotherapy
0%450 mg
NCT05499130 · Phase 2b · monotherapy
Discontinued due to AEs
0%1800 mga
NCT05499130 · Phase 2b · monotherapy
show 5 more results
0%1800 mg
NCT05499130 · Phase 2b · monotherapy
2.1%900 mg
NCT05499130 · Phase 2b · monotherapy
2.2%900 mg
NCT05499130 · Phase 2b · monotherapy
8.7%450 mg
NCT05499130 · Phase 2b · monotherapy
0%450 mg
NCT05499130 · Phase 2b · monotherapy
Serious AEs
0%1800 mga
NCT05499130 · Phase 2b · monotherapy
show 5 more results
0%1800 mg
NCT05499130 · Phase 2b · monotherapy
2.2%900 mg
NCT05499130 · Phase 2b · monotherapy
2.2%900 mg
NCT05499130 · Phase 2b · monotherapy
13%450 mg
NCT05499130 · Phase 2b · monotherapy
0%450 mg
NCT05499130 · Phase 2b · monotherapy
Most frequent reported AEs
1800 mga
eczema 33.3% (placebo 0%)
influenza 33.3% (placebo 2.2%)
proteinuria 33.3% (placebo 0%)
NCT05499130 · Phase 2b · monotherapy
show 5 more results
1800 mg
abnormal uterine bleeding 14.3% (placebo 0%)
insomnia 14.3% (placebo 0%)
anaemia 0% (placebo 2.2%)
NCT05499130 · Phase 2b · monotherapy
900 mg
nasopharyngitis 6.5% (placebo 6.5%)
headache 2.2% (placebo 2.2%)
vomiting 2.2% (placebo 4.3%)
NCT05499130 · Phase 2b · monotherapy
900 mg
headache 4.3% (placebo 2.2%)
influenza 4.3% (placebo 2.2%)
anaemia 2.2% (placebo 2.2%)
NCT05499130 · Phase 2b · monotherapy
450 mg
headache 8.7% (placebo 2.2%)
anaemia 6.5% (placebo 2.2%)
nasopharyngitis 4.3% (placebo 6.5%)
NCT05499130 · Phase 2b · monotherapy
450 mg
nasopharyngitis 6.4% (placebo 6.5%)
upper respiratory tract infection 6.4% (placebo 4.3%)
vomiting 6.4% (placebo 4.3%)
NCT05499130 · Phase 2b · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

duvakitug

Endoscopic 47.8% (n=46) vs 13% (n=46) placebo @ 14wk900 mg
responder rate · % of participants
NCT05499130 · Phase 2b · monotherapy · converted to % from 22 Participants as posted
show 3 more results
39.1% (n=46) vs 13% (n=46) placebo @ 14wk*900 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 18 Participants as posted
26.1% (n=46) vs 13% (n=46) placebo @ 14wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 12 Participants as posted
34.8% (n=46) vs 13% (n=46) placebo @ 14wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 16 Participants as posted
Clinical Response 39.1% (n=46) vs 32.6% (n=46) placebo @ 4wk900 mg
responder rate · % of participants
NCT05499130 · Phase 2b · monotherapy · converted to % from 18 Participants as posted
show 9 more results
54.3% (n=46) vs 41.3% (n=46) placebo @ 8wk*900 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 25 Participants as posted
67.4% (n=46) vs 47.8% (n=46) placebo @ 12wk*900 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 31 Participants as posted
65.2% (n=46) vs 52.2% (n=46) placebo @ 14wk*900 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 30 Participants as posted
30.4% (n=46) vs 17.4% (n=46) placebo @ 14wk*900 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 14 Participants as posted
52.2% (n=46) vs 32.6% (n=46) placebo @ 4wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 24 Participants as posted
65.2% (n=46) vs 41.3% (n=46) placebo @ 8wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 30 Participants as posted
67.4% (n=46) vs 47.8% (n=46) placebo @ 12wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 31 Participants as posted
65.2% (n=46) vs 52.2% (n=46) placebo @ 14wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 30 Participants as posted
34.8% (n=46) vs 17.4% (n=46) placebo @ 14wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 16 Participants as posted
Clinical Remission 54.3% (n=46) vs 41.3% (n=46) placebo @ 14wk900 mg
responder rate · % of participants
NCT05499130 · Phase 2b · monotherapy · converted to % from 25 Participants as posted
show 3 more results
37% (n=46) vs 26.1% (n=46) placebo @ 14wk*900 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 17 Participants as posted
50% (n=46) vs 41.3% (n=46) placebo @ 14wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 23 Participants as posted
37% (n=46) vs 26.1% (n=46) placebo @ 14wk*450 mg
NCT05499130 · Phase 2b · monotherapy · converted to % from 17 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: afimkibart's landscape · duvakitug's landscape